Global Long-acting PrEP Market Research Report 2026

Long-acting PrEP Market

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on Long-acting PrEP competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.

Long-acting PrEP refers to HIV pre-exposure prophylaxis delivered through formulations or delivery systems that sustain protective drug exposure over extended periods, shifting prevention from daily or event-driven pill-taking to dosing or device replacement at monthly, quarterly, semiannual, or even longer intervals. The primary problem it addresses is the real-world persistence and access gap seen with oral PrEP: many people who would benefit from prevention struggle with continuous daily adherence, timely refills, discreet storage and use, or consistent engagement with care, and fluctuating risk patterns can make stop–start cycles especially prone to protection gaps. By reducing dosing frequency and the day-to-day behavioral burden, long-acting PrEP aims to increase the likelihood of uninterrupted protection while enabling prevention to be packaged more naturally with follow-up, testing, and broader sexual health services. Its product history can be viewed in stages: oral PrEP first established efficacy and became embedded in guidelines and practice; the field then leveraged advances from long-acting HIV treatment—such as micro-/nano-crystal depot technologies, stable injectable formulations, aseptic manufacturing, and cold-chain logistics—to enable the first wave of long-acting PrEP commercialization; and current development is focused on extending duration and diversifying modalities, including longer-interval small-molecule injections, controlled-release implants, and biologics-based approaches with the potential for even less frequent administration. Upstream, long-acting PrEP depends on both conventional pharmaceutical inputs and a more demanding formulation-and-device supply chain: APIs and key intermediates; chemical reagents, catalysts, and solvents; injection- or implant-grade excipients (surfactants, stabilizers, buffers, water for injection, and medical-grade polymers); and the components and consumables required for aseptic production and delivery (injectable-grade glass containers, elastomer stoppers/plungers, seals, needles and safety injection devices, prefilled systems, sterilizing filters, single-use tubing and filling sets, labels, and cold-chain packaging), supported by specialized suppliers providing aseptic fill-finish, sterilization validation, temperature-controlled transport, and quality-system services.In 2025, the global production capacity of long-acting PrEP reached 150,000 doses, while total sales amounted to 117,200 doses. The average selling price was USD 2,660 per dose, and manufacturers’ gross margins ranged between 60% and 70%.

The current long-acting PrEP market is characterized by rising awareness and uneven delivery capacity. Clinical and public health stakeholders increasingly view long-acting options as essential for reaching people who struggle with persistence on oral regimens, yet uptake is often constrained by the practical realities of care delivery—reliable follow-up pathways, standardized testing and risk assessment, trained personnel, and tighter inventory and cold-chain discipline. Differences across countries and regions in reimbursement design, provider networks, stigma, and access for priority populations create markedly different adoption trajectories. As a result, competition today is as much about building a sustainable service model as it is about the medicine itself: streamlined patient journeys, integration with sexual health services, community-based outreach, and models tailored to younger or highly mobile groups.

Looking forward, the market is likely to evolve through a combination of technology diversification and service decentralization. On the technology side, development efforts are converging on longer dosing intervals, fewer touchpoints with the health system, improved tolerability, and more flexible user options, with multiple modalities advancing in parallel and enabling differentiated product portfolios. In parallel, real-world success will depend increasingly on complementary delivery innovations—risk-stratified follow-up that avoids unnecessary visits, expanded roles for community providers and pharmacies, digital support for continuity, and smoother “start–pause–restart” pathways. The market will also become more segmented, with different prevention packages emerging for different exposure patterns and social contexts, shifting differentiation from efficacy alone toward sustained user experience and system efficiency.

Key drivers include the alignment of public health priorities with user preferences for prevention that is easier to maintain and more discreet, along with steady progress in formulation and manufacturing that supports broader scale-up. Payers and providers also have growing incentives to adopt models that emphasize outcomes and continuity rather than repeated transactional visits. At the same time, barriers remain substantial: reliance on clinical infrastructure can slow decentralization, concerns about long drug “tail,” injection-site effects, and reversibility can deter initiation for some, and stigma and privacy dynamics continue to influence both demand and engagement. Supply-side complexity—aseptic manufacturing, cold-chain logistics, and reliable component availability—adds another layer of fragility. Ultimately, expansion is likely to be strongest where payment policy, delivery networks, and community engagement reinforce one another, enabling long-acting prevention to function as a durable system rather than a standalone intervention.

This report delivers a comprehensive overview of the global Long-acting PrEP market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Long-acting PrEP. The Long-acting PrEP market size, estimates, and forecasts are provided in terms of sales volume (K Dose) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global Long-acting PrEP market comprehensively. Regional market sizes by Type, by Application, by Dosing Interval, and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist Long-acting PrEP manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Market Segmentation

Scope of Long-acting PrEP Market Report

Chapter Outline

1.1 Product Definition

1.2 Long-acting PrEP by Type

1.2.1 Global Long-acting PrEP Market Value by Type: 2025 vs 2032

1.2.2 Cabotegravir

1.2.3 Lenacapavir

1.2.4 Other

1.3 Long-acting PrEP by Dosing Interval

1.3.1 Global Long-acting PrEP Market Value by Dosing Interval: 2025 vs 2032

1.3.2 Short-interval Injections

1.3.3 Monthly Injections

1.3.4 Quarterly Injections

1.4 Long-acting PrEP by Drug Properties

1.4.1 Global Long-acting PrEP Market Value by Drug Properties: 2025 vs 2032

1.4.2 Original Drug

1.4.3 Generic Drug

1.5 Long-acting PrEP by Application

1.5.1 Global Long-acting PrEP Market Value by Application: 2025 vs 2032

1.5.2 Hospital

1.5.3 Clinic

1.5.4 Other

1.6 Global Long-acting PrEP Market Size Estimates and Forecasts

1.6.1 Global Long-acting PrEP Revenue 2021–2032

1.6.2 Global Long-acting PrEP Sales 2021–2032

1.6.3 Global Long-acting PrEP Market Average Price (2021–2032)

1.7 Assumptions and Limitations

2.1 Global Long-acting PrEP Sales Market Share by Manufacturers (2021–2026)

2.2 Global Long-acting PrEP Revenue Market Share by Manufacturers (2021–2026)

2.3 Global Long-acting PrEP Average Price by Manufacturers (2021–2026)

2.4 Global Key Players of Long-acting PrEP, Industry Ranking, 2023 vs 2024 vs 2025

2.5 Global Key Manufacturers of Long-acting PrEP, Manufacturing Sites and Headquarters

2.6 Global Key Manufacturers of Long-acting PrEP, Product Types and Applications

2.7 Global Key Manufacturers of Long-acting PrEP, Date of Entry into the Industry

2.8 Global Long-acting PrEP Market Competitive Situation and Trends

2.8.1 Global Long-acting PrEP Market Concentration Rate

2.8.2 The Top 5 and Top 10 Global Long-acting PrEP Players Market Share by Revenue

2.8.3 Global Long-acting PrEP Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3.1 Global Long-acting PrEP Market Size by Region: 2021 vs 2025 vs 2032

3.2 Global Long-acting PrEP Sales by Region: 2021–2032

3.2.1 Global Long-acting PrEP Sales by Region: 2021–2026

3.2.2 Global Long-acting PrEP Sales by Region: 2027–2032

3.3 Global Long-acting PrEP Revenue by Region: 2021–2032

3.3.1 Global Long-acting PrEP Revenue by Region: 2021–2026

3.3.2 Global Long-acting PrEP Revenue by Region: 2027–2032

3.4 North America Long-acting PrEP Market Facts & Figures by Country

3.4.1 North America Long-acting PrEP Market Size by Country: 2021 vs 2025 vs 2032

3.4.2 North America Long-acting PrEP Sales by Country (2021–2032)

3.4.3 North America Long-acting PrEP Revenue by Country (2021–2032)

3.4.4 United States

3.4.5 Canada

3.5 Europe Long-acting PrEP Market Facts & Figures by Country

3.5.1 Europe Long-acting PrEP Market Size by Country: 2021 vs 2025 vs 2032

3.5.2 Europe Long-acting PrEP Sales by Country (2021–2032)

3.5.3 Europe Long-acting PrEP Revenue by Country (2021–2032)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Long-acting PrEP Market Facts & Figures by Region

3.6.1 Asia Pacific Long-acting PrEP Market Size by Region: 2021 vs 2025 vs 2032

3.6.2 Asia Pacific Long-acting PrEP Sales by Region (2021–2032)

3.6.3 Asia Pacific Long-acting PrEP Revenue by Region (2021–2032)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America Long-acting PrEP Market Facts & Figures by Country

3.7.1 Latin America Long-acting PrEP Market Size by Country: 2021 vs 2025 vs 2032

3.7.2 Latin America Long-acting PrEP Sales by Country (2021–2032)

3.7.3 Latin America Long-acting PrEP Revenue by Country (2021–2032)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.7.7 Colombia

3.8 Middle East and Africa Long-acting PrEP Market Facts & Figures by Country

3.8.1 Middle East and Africa Long-acting PrEP Market Size by Country: 2021 vs 2025 vs 2032

3.8.2 Middle East and Africa Long-acting PrEP Sales by Country (2021–2032)

3.8.3 Middle East and Africa Long-acting PrEP Revenue by Country (2021–2032)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4.1 Global Long-acting PrEP Sales by Type (2021–2032)

4.1.1 Global Long-acting PrEP Sales by Type (2021–2026)

4.1.2 Global Long-acting PrEP Sales by Type (2027–2032)

4.1.3 Global Long-acting PrEP Sales Market Share by Type (2021–2032)

4.2 Global Long-acting PrEP Revenue by Type (2021–2032)

4.2.1 Global Long-acting PrEP Revenue by Type (2021–2026)

4.2.2 Global Long-acting PrEP Revenue by Type (2027–2032)

4.2.3 Global Long-acting PrEP Revenue Market Share by Type (2021–2032)

4.3 Global Long-acting PrEP Price by Type (2021–2032)

5.1 Global Long-acting PrEP Sales by Application (2021–2032)

5.1.1 Global Long-acting PrEP Sales by Application (2021–2026)

5.1.2 Global Long-acting PrEP Sales by Application (2027–2032)

5.1.3 Global Long-acting PrEP Sales Market Share by Application (2021–2032)

5.2 Global Long-acting PrEP Revenue by Application (2021–2032)

5.2.1 Global Long-acting PrEP Revenue by Application (2021–2026)

5.2.2 Global Long-acting PrEP Revenue by Application (2027–2032)

5.2.3 Global Long-acting PrEP Revenue Market Share by Application (2021–2032)

5.3 Global Long-acting PrEP Price by Application (2021–2032)

6.1 Gilead Sciences

6.1.1 Gilead Sciences Company Information

6.1.2 Gilead Sciences Description and Business Overview

6.1.3 Gilead Sciences Long-acting PrEP Sales, Revenue, and Gross Margin (2021–2026)

6.1.4 Gilead Sciences Long-acting PrEP Product Portfolio

6.1.5 Gilead Sciences Recent Developments/Updates

6.2 ViiV Healthcare

6.2.1 ViiV Healthcare Company Information

6.2.2 ViiV Healthcare Description and Business Overview

6.2.3 ViiV Healthcare Long-acting PrEP Sales, Revenue, and Gross Margin (2021–2026)

6.2.4 ViiV Healthcare Long-acting PrEP Product Portfolio

6.2.5 ViiV Healthcare Recent Developments/Updates

7.1 Long-acting PrEP Industry Chain Analysis

7.2 Long-acting PrEP Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Long-acting PrEP Production Mode & Process Analysis

7.4 Long-acting PrEP Sales and Marketing

7.4.1 Long-acting PrEP Sales Channels

7.4.2 Long-acting PrEP Distributors

7.5 Long-acting PrEP Customer Analysis

8.1 Long-acting PrEP Industry Trends

8.2 Long-acting PrEP Market Drivers

8.3 Long-acting PrEP Market Challenges

8.4 Long-acting PrEP Market Restraints

8.5 Impact of U.S. Tariffs

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

List of Tables

 Table 1. Global Long-acting PrEP Market Value by Type (US$ Million), 2025 vs 2032

 Table 2. Global Long-acting PrEP Market Value by Dosing Interval (US$ Million), 2025 vs 2032

 Table 3. Global Long-acting PrEP Market Value by Drug Properties (US$ Million), 2025 vs 2032

 Table 4. Global Long-acting PrEP Market Value by Application (US$ Million), 2025 vs 2032

 Table 5. Global Long-acting PrEP Market Competitive Situation by Manufacturers in 2025

 Table 6. Global Long-acting PrEP Sales (K Dose) of Key Manufacturers (2021–2026)

 Table 7. Global Long-acting PrEP Sales Market Share by Manufacturers (2021–2026)

 Table 8. Global Long-acting PrEP Revenue (US$ Million) by Manufacturers (2021–2026)

 Table 9. Global Long-acting PrEP Revenue Share by Manufacturers (2021–2026)

 Table 10. Global Market Long-acting PrEP Average Price (US$/Dose) of Key Manufacturers (2021–2026)

 Table 11. Global Key Players of Long-acting PrEP, Industry Ranking, 2023 vs 2024 vs 2025

 Table 12. Global Key Manufacturers of Long-acting PrEP, Manufacturing Sites and Headquarters

 Table 13. Global Key Manufacturers of Long-acting PrEP, Product Types and Applications

 Table 14. Global Key Manufacturers of Long-acting PrEP, Date of Entry into the Industry

 Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

 Table 16. Global Long-acting PrEP Companies by Tier (Tier 1, Tier 2, Tier 3), based on Long-acting PrEP Revenue, 2025

 Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans

 Table 18. Global Long-acting PrEP Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

 Table 19. Global Long-acting PrEP Sales by Region (K Dose), 2021–2026

 Table 20. Global Long-acting PrEP Sales Market Share by Region (2021–2026)

 Table 21. Global Long-acting PrEP Sales by Region (K Dose), 2027–2032

 Table 22. Global Long-acting PrEP Sales Market Share by Region (2027–2032)

 Table 23. Global Long-acting PrEP Revenue by Region (US$ Million), 2021–2026

 Table 24. Global Long-acting PrEP Revenue Market Share by Region (2021–2026)

 Table 25. Global Long-acting PrEP Revenue by Region (US$ Million), 2027–2032

 Table 26. Global Long-acting PrEP Revenue Market Share by Region (2027–2032)

 Table 27. North America Long-acting PrEP Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

 Table 28. North America Long-acting PrEP Sales by Country (K Dose), 2021–2026

 Table 29. North America Long-acting PrEP Sales by Country (K Dose), 2027–2032

 Table 30. North America Long-acting PrEP Revenue by Country (US$ Million), 2021–2026

 Table 31. North America Long-acting PrEP Revenue by Country (US$ Million), 2027–2032

 Table 32. Europe Long-acting PrEP Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

 Table 33. Europe Long-acting PrEP Sales by Country (K Dose), 2021–2026

 Table 34. Europe Long-acting PrEP Sales by Country (K Dose), 2027–2032

 Table 35. Europe Long-acting PrEP Revenue by Country (US$ Million), 2021–2026

 Table 36. Europe Long-acting PrEP Revenue by Country (US$ Million), 2027–2032

 Table 37. Asia Pacific Long-acting PrEP Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)

 Table 38. Asia Pacific Long-acting PrEP Sales by Region (K Dose), 2021–2026

 Table 39. Asia Pacific Long-acting PrEP Sales by Region (K Dose), 2027–2032

 Table 40. Asia Pacific Long-acting PrEP Revenue by Region (US$ Million), 2021–2026

 Table 41. Asia Pacific Long-acting PrEP Revenue by Region (US$ Million), 2027–2032

 Table 42. Latin America Long-acting PrEP Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

 Table 43. Latin America Long-acting PrEP Sales by Country (K Dose), 2021–2026

 Table 44. Latin America Long-acting PrEP Sales by Country (K Dose), 2027–2032

 Table 45. Latin America Long-acting PrEP Revenue by Country (US$ Million), 2021–2026

 Table 46. Latin America Long-acting PrEP Revenue by Country (US$ Million), 2027–2032

 Table 47. Middle East and Africa Long-acting PrEP Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

 Table 48. Middle East and Africa Long-acting PrEP Sales by Country (K Dose), 2021–2026

 Table 49. Middle East and Africa Long-acting PrEP Sales by Country (K Dose), 2027–2032

 Table 50. Middle East and Africa Long-acting PrEP Revenue by Country (US$ Million), 2021–2026

 Table 51. Middle East and Africa Long-acting PrEP Revenue by Country (US$ Million), 2027–2032

 Table 52. Global Long-acting PrEP Sales (K Dose) by Type (2021–2026)

 Table 53. Global Long-acting PrEP Sales (K Dose) by Type (2027–2032)

 Table 54. Global Long-acting PrEP Sales Market Share by Type (2021–2026)

 Table 55. Global Long-acting PrEP Sales Market Share by Type (2027–2032)

 Table 56. Global Long-acting PrEP Revenue (US$ Million) by Type (2021–2026)

 Table 57. Global Long-acting PrEP Revenue (US$ Million) by Type (2027–2032)

 Table 58. Global Long-acting PrEP Revenue Market Share by Type (2021–2026)

 Table 59. Global Long-acting PrEP Revenue Market Share by Type (2027–2032)

 Table 60. Global Long-acting PrEP Price (US$/Dose) by Type (2021–2026)

 Table 61. Global Long-acting PrEP Price (US$/Dose) by Type (2027–2032)

 Table 62. Global Long-acting PrEP Sales (K Dose) by Application (2021–2026)

 Table 63. Global Long-acting PrEP Sales (K Dose) by Application (2027–2032)

 Table 64. Global Long-acting PrEP Sales Market Share by Application (2021–2026)

 Table 65. Global Long-acting PrEP Sales Market Share by Application (2027–2032)

 Table 66. Global Long-acting PrEP Revenue (US$ Million) by Application (2021–2026)

 Table 67. Global Long-acting PrEP Revenue (US$ Million) by Application (2027–2032)

 Table 68. Global Long-acting PrEP Revenue Market Share by Application (2021–2026)

 Table 69. Global Long-acting PrEP Revenue Market Share by Application (2027–2032)

 Table 70. Global Long-acting PrEP Price (US$/Dose) by Application (2021–2026)

 Table 71. Global Long-acting PrEP Price (US$/Dose) by Application (2027–2032)

 Table 72. Gilead Sciences Company Information

 Table 73. Gilead Sciences Description and Business Overview

 Table 74. Gilead Sciences Long-acting PrEP Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)

 Table 75. Gilead Sciences Long-acting PrEP Product

 Table 76. Gilead Sciences Recent Developments/Updates

 Table 77. ViiV Healthcare Company Information

 Table 78. ViiV Healthcare Description and Business Overview

 Table 79. ViiV Healthcare Long-acting PrEP Sales (K Dose), Revenue (US$ Million), Price (US$/Dose), and Gross Margin (2021–2026)

 Table 80. ViiV Healthcare Long-acting PrEP Product

 Table 81. ViiV Healthcare Recent Developments/Updates

 Table 82. Key Raw Materials Lists

 Table 83. Raw Materials Key Suppliers Lists

 Table 84. Long-acting PrEP Distributors List

 Table 85. Long-acting PrEP Customers List

 Table 86. Long-acting PrEP Market Trends

 Table 87. Long-acting PrEP Market Drivers

 Table 88. Long-acting PrEP Market Challenges

 Table 89. Long-acting PrEP Market Restraints

 Table 90. Research Programs/Design for This Report

 Table 91. Key Data Information from Secondary Sources

 Table 92. Key Data Information from Primary Sources

 Table 93. Authors List of This Report

List of Figures

 Figure 1. Product Picture of Long-acting PrEP

 Figure 2. Global Long-acting PrEP Market Value by Type (US$ Million), 2021–2032

 Figure 3. Global Long-acting PrEP Market Share by Type: 2025 & 2032

 Figure 4. Cabotegravir Product Picture

 Figure 5. Lenacapavir Product Picture

 Figure 6. Other Product Picture

 Figure 7. Global Long-acting PrEP Market Value by Dosing Interval (US$ Million), 2021–2032

 Figure 8. Global Long-acting PrEP Market Share by Dosing Interval: 2025 vs 2032

 Figure 9. Short-interval Injections Product Picture

 Figure 10. Monthly Injections Product Picture

 Figure 11. Quarterly Injections Product Picture

 Figure 12. Global Long-acting PrEP Market Value by Drug Properties (US$ Million), 2021–2032

 Figure 13. Global Long-acting PrEP Market Share by Drug Properties: 2025 vs 2032

 Figure 14. Original Drug Product Picture

 Figure 15. Generic Drug Product Picture

 Figure 16. Global Long-acting PrEP Market Value by Application (US$ Million), 2021–2032

 Figure 17. Global Long-acting PrEP Market Share by Application: 2025 & 2032

 Figure 18. Hospital

 Figure 19. Clinic

 Figure 20. Other

 Figure 21. Global Long-acting PrEP Revenue, (US$ Million), 2021 vs 2025 vs 2032

 Figure 22. Global Long-acting PrEP Market Size (US$ Million), 2021–2032

 Figure 23. Global Long-acting PrEP Sales (K Dose), 2021–2032

 Figure 24. Global Long-acting PrEP Average Price (US$/Dose), 2021–2032

 Figure 25. Long-acting PrEP Report Years Considered

 Figure 26. Long-acting PrEP Sales Share by Manufacturers in 2025

 Figure 27. Global Long-acting PrEP Revenue Share by Manufacturers in 2025

 Figure 28. Top 5 and Top 10 Global Long-acting PrEP Players: Market Share by Revenue in Long-acting PrEP in 2025

 Figure 29. Long-acting PrEP Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025

 Figure 30. Global Long-acting PrEP Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

 Figure 31. North America Long-acting PrEP Sales Market Share by Country (2021–2032)

 Figure 32. North America Long-acting PrEP Revenue Market Share by Country (2021–2032)

 Figure 33. United States Long-acting PrEP Revenue Growth Rate (US$ Million), 2021–2032

 Figure 34. Canada Long-acting PrEP Revenue Growth Rate (US$ Million), 2021–2032

 Figure 35. Europe Long-acting PrEP Sales Market Share by Country (2021–2032)

 Figure 36. Europe Long-acting PrEP Revenue Market Share by Country (2021–2032)

 Figure 37. Germany Long-acting PrEP Revenue Growth Rate (US$ Million), 2021–2032

 Figure 38. France Long-acting PrEP Revenue Growth Rate (US$ Million), 2021–2032

 Figure 39. U.K. Long-acting PrEP Revenue Growth Rate (US$ Million), 2021–2032

 Figure 40. Italy Long-acting PrEP Revenue Growth Rate (US$ Million), 2021–2032

 Figure 41. Russia Long-acting PrEP Revenue Growth Rate (US$ Million), 2021–2032

 Figure 42. Asia Pacific Long-acting PrEP Sales Market Share by Region (2021–2032)

 Figure 43. Asia Pacific Long-acting PrEP Revenue Market Share by Region (2021–2032)

 Figure 44. China Long-acting PrEP Revenue Growth Rate (US$ Million), 2021–2032

 Figure 45. Japan Long-acting PrEP Revenue Growth Rate (US$ Million), 2021–2032

 Figure 46. South Korea Long-acting PrEP Revenue Growth Rate (US$ Million), 2021–2032

 Figure 47. India Long-acting PrEP Revenue Growth Rate (US$ Million), 2021–2032

 Figure 48. Australia Long-acting PrEP Revenue Growth Rate (US$ Million), 2021–2032

 Figure 49. China Taiwan Long-acting PrEP Revenue Growth Rate (US$ Million), 2021–2032

 Figure 50. Southeast Asia Long-acting PrEP Revenue Growth Rate (US$ Million), 2021–2032

 Figure 51. Latin America Long-acting PrEP Sales Market Share by Country (2021–2032)

 Figure 52. Latin America Long-acting PrEP Revenue Market Share by Country (2021–2032)

 Figure 53. Mexico Long-acting PrEP Revenue Growth Rate (US$ Million), 2021–2032

 Figure 54. Brazil Long-acting PrEP Revenue Growth Rate (US$ Million), 2021–2032

 Figure 55. Argentina Long-acting PrEP Revenue Growth Rate (US$ Million), 2021–2032

 Figure 56. Colombia Long-acting PrEP Revenue Growth Rate (US$ Million), 2021–2032

 Figure 57. Middle East and Africa Long-acting PrEP Sales Market Share by Country (2021–2032)

 Figure 58. Middle East and Africa Long-acting PrEP Revenue Market Share by Country (2021–2032)

 Figure 59. Turkey Long-acting PrEP Revenue Growth Rate (US$ Million), 2021–2032

 Figure 60. Saudi Arabia Long-acting PrEP Revenue Growth Rate (US$ Million), 2021–2032

 Figure 61. UAE Long-acting PrEP Revenue Growth Rate (US$ Million), 2021–2032

 Figure 62. Global Sales Market Share of Long-acting PrEP by Type (2021–2032)

 Figure 63. Global Revenue Market Share of Long-acting PrEP by Type (2021–2032)

 Figure 64. Global Long-acting PrEP Price (US$/Dose) by Type (2021–2032)

 Figure 65. Global Sales Market Share of Long-acting PrEP by Application (2021–2032)

 Figure 66. Global Revenue Market Share of Long-acting PrEP by Application (2021–2032)

 Figure 67. Global Long-acting PrEP Price (US$/Dose) by Application (2021–2032)

 Figure 68. Long-acting PrEP Value Chain

 Figure 69. Channels of Distribution (Direct Vs Distribution)

 Figure 70. Bottom-up and Top-down Approaches for This Report

 Figure 71. Data Triangulation

 Figure 72. Key Executives Interviewed